Engineering mesoporous silica nanoparticles towards oral delivery of vancomycin.

Administration, Oral Anti-Bacterial Agents / administration & dosage Biocompatible Materials / chemistry Biological Availability Caco-2 Cells Cell Survival / drug effects Cells, Cultured Drug Delivery Systems Humans Hydrophobic and Hydrophilic Interactions Materials Testing Molecular Structure Nanoparticles / chemistry Particle Size Porosity Silicon Dioxide / chemistry Surface Properties Vancomycin / administration & dosage

Journal

Journal of materials chemistry. B
ISSN: 2050-7518
Titre abrégé: J Mater Chem B
Pays: England
ID NLM: 101598493

Informations de publication

Date de publication:
15 09 2021
Historique:
entrez: 15 9 2021
pubmed: 16 9 2021
medline: 4 2 2022
Statut: epublish

Résumé

Vancomycin (Van) is a key antibiotic of choice for the treatment of systemic methicillin resistant

Identifiants

DOI: 10.1039/d1tb01430g PMID: 34525166
pubmed: 34525166
doi: 10.1039/d1tb01430g
doi:

Substances chimiques

Anti-Bacterial Agents 0
Biocompatible Materials 0
Vancomycin 6Q205EH1VU
Silicon Dioxide 7631-86-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7145-7166

Auteurs

John Ndayishimiye (J)

School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Brisbane, Queensland 4102, Australia. a.popat@uq.edu.au.
ORCID: 0000-0001-7679-9013

Yuxue Cao (Y)

School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Brisbane, Queensland 4102, Australia. a.popat@uq.edu.au.

Tushar Kumeria (T)

School of Materials Science and Engineering, University of New South Wales, New South Wales, Australia.
ORCID: 0000-0003-3351-7148

Mark A T Blaskovich (MAT)

Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland 4072, Australia.
ORCID: 0000-0001-9447-2292

James Robert Falconer (JR)

School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Brisbane, Queensland 4102, Australia. a.popat@uq.edu.au.

Amirali Popat (A)

School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Brisbane, Queensland 4102, Australia. a.popat@uq.edu.au.
Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia.
ORCID: 0000-0001-5401-3446

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Matériaux biocompatibles › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Biodisponibilité › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules Caco-2 › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Cellules › Cellules cultivées › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Phénomènes chimiques › Interactions hydrophobes et hydrophiles › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Techniques d'investigation › Test de matériaux › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Phénomènes chimiques › Taille de particule › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Phénomènes physiques › Phénomènes mécaniques › Porosité › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du silicium › Silice › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Phénomènes chimiques › Propriétés de surface › Engineering mesoporous silica nanoparticles...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Vancomycine › Engineering mesoporous silica nanoparticles...